[A18-57] Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 13.02.2019
Project no.:
A18-57
Commission:
Commission awarded on 19.09.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy
Added benefit not proven for the 2 subindications (no liver cirrhosis or stage Child-Pugh A, Child-Pugh B)
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2019-01-02.After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-19 | Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-15 | Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57 | Commission completed |
| G15-06 | Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A16-63 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-122 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-160 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-162 | Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.